Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: An intention to mobilize and transplant analysis

Attilio Olivieri, Marino Brunori, Debora Capelli, Mauro Montanari, Danilo Massidda, Guido Gini, Moira Lucesole, Antonella Poloni, Massimo Offidani, Marco Candela, Riccardo Centurioni, Pietro Leoni

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Chemotherapy followed by autologous transplantation may be an efficient salvage treatment in malignant lymphomas. We investigated the feasibility, tolerability and efficacy of an outpatient schedule of dexamethasone, cytarabine and cisplatin (DHAP), followed by peripheral blood progenitor cell autografting as salvage treatment in patients with high grade (HG), low grade (LG) non-Hodgkin's lymphoma (NHL) and Hodgkin's Disease (HD). A total of 159 DHAP courses (median: 2, range: 1-5), was administered on outpatient basis to 79 patients (31 LG-NHL, 28 HG-NHL and 20 HD), with the intention to mobilize and to transplant. A successful collection was not achieved in 40% LG-NHL, 10% HD and 20% HG-NHL patients. The risk to fail the collection was significantly related to the number of previous chemotherapy courses (>6) (P = 0.005, RR = 1.4), to the pretransplant status (P = 0.04, RR = 13.5) and to the previous fludarabine administration (P = 0.01, RR = 20). High dose therapy (HDT) was feasible in 60 patients (76%). The overall treatment related mortality was 3.8%. The overall response rate (ORR) was 81% with a 57.6% overall survival (OS) at 62 months (95% CI: 45-69.3%) and a progression free survival (PFS) of 42% at 74 months (95% CI: 26.7-58%). The diagnosis of HG-NHL and the non-response to DHAP resulted to reduce respectively the OS (P = 0.007, RR = 2.8) and PFS probability (P = 0.01, RR = 4.1). In conclusion this outpatient schedule of DHAP is a well tolerated, efficient salvage and mobilizing regimen not only in HG-NHL, but also in LG-NHL and in HD. Randomized studies are needed to better define the role of DHAP in LG-NHL and HD patients.

Original languageEnglish
Pages (from-to)10-17
Number of pages8
JournalEuropean Journal of Haematology
Volume72
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Salvage Therapy
Non-Hodgkin's Lymphoma
Lymphoma
Appointments and Schedules
Outpatients
Transplantation
Transplants
Hodgkin Disease
Autologous Transplantation
Disease-Free Survival
Drug Therapy
Survival
Cytarabine
Dexamethasone
Cisplatin
Blood Cells
Stem Cells

Keywords

  • Autologous transplant
  • DHAP
  • Mobilization
  • Non-Hodgkin lymphoma
  • Relapse

ASJC Scopus subject areas

  • Hematology

Cite this

Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients : An intention to mobilize and transplant analysis. / Olivieri, Attilio; Brunori, Marino; Capelli, Debora; Montanari, Mauro; Massidda, Danilo; Gini, Guido; Lucesole, Moira; Poloni, Antonella; Offidani, Massimo; Candela, Marco; Centurioni, Riccardo; Leoni, Pietro.

In: European Journal of Haematology, Vol. 72, No. 1, 01.2004, p. 10-17.

Research output: Contribution to journalArticle

Olivieri, A, Brunori, M, Capelli, D, Montanari, M, Massidda, D, Gini, G, Lucesole, M, Poloni, A, Offidani, M, Candela, M, Centurioni, R & Leoni, P 2004, 'Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: An intention to mobilize and transplant analysis', European Journal of Haematology, vol. 72, no. 1, pp. 10-17. https://doi.org/10.1046/j.0902-4441.2004.00171.x
Olivieri, Attilio ; Brunori, Marino ; Capelli, Debora ; Montanari, Mauro ; Massidda, Danilo ; Gini, Guido ; Lucesole, Moira ; Poloni, Antonella ; Offidani, Massimo ; Candela, Marco ; Centurioni, Riccardo ; Leoni, Pietro. / Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients : An intention to mobilize and transplant analysis. In: European Journal of Haematology. 2004 ; Vol. 72, No. 1. pp. 10-17.
@article{ee76ba07bec6486e95ef0526d1a2285b,
title = "Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: An intention to mobilize and transplant analysis",
abstract = "Chemotherapy followed by autologous transplantation may be an efficient salvage treatment in malignant lymphomas. We investigated the feasibility, tolerability and efficacy of an outpatient schedule of dexamethasone, cytarabine and cisplatin (DHAP), followed by peripheral blood progenitor cell autografting as salvage treatment in patients with high grade (HG), low grade (LG) non-Hodgkin's lymphoma (NHL) and Hodgkin's Disease (HD). A total of 159 DHAP courses (median: 2, range: 1-5), was administered on outpatient basis to 79 patients (31 LG-NHL, 28 HG-NHL and 20 HD), with the intention to mobilize and to transplant. A successful collection was not achieved in 40{\%} LG-NHL, 10{\%} HD and 20{\%} HG-NHL patients. The risk to fail the collection was significantly related to the number of previous chemotherapy courses (>6) (P = 0.005, RR = 1.4), to the pretransplant status (P = 0.04, RR = 13.5) and to the previous fludarabine administration (P = 0.01, RR = 20). High dose therapy (HDT) was feasible in 60 patients (76{\%}). The overall treatment related mortality was 3.8{\%}. The overall response rate (ORR) was 81{\%} with a 57.6{\%} overall survival (OS) at 62 months (95{\%} CI: 45-69.3{\%}) and a progression free survival (PFS) of 42{\%} at 74 months (95{\%} CI: 26.7-58{\%}). The diagnosis of HG-NHL and the non-response to DHAP resulted to reduce respectively the OS (P = 0.007, RR = 2.8) and PFS probability (P = 0.01, RR = 4.1). In conclusion this outpatient schedule of DHAP is a well tolerated, efficient salvage and mobilizing regimen not only in HG-NHL, but also in LG-NHL and in HD. Randomized studies are needed to better define the role of DHAP in LG-NHL and HD patients.",
keywords = "Autologous transplant, DHAP, Mobilization, Non-Hodgkin lymphoma, Relapse",
author = "Attilio Olivieri and Marino Brunori and Debora Capelli and Mauro Montanari and Danilo Massidda and Guido Gini and Moira Lucesole and Antonella Poloni and Massimo Offidani and Marco Candela and Riccardo Centurioni and Pietro Leoni",
year = "2004",
month = "1",
doi = "10.1046/j.0902-4441.2004.00171.x",
language = "English",
volume = "72",
pages = "10--17",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "1",

}

TY - JOUR

T1 - Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients

T2 - An intention to mobilize and transplant analysis

AU - Olivieri, Attilio

AU - Brunori, Marino

AU - Capelli, Debora

AU - Montanari, Mauro

AU - Massidda, Danilo

AU - Gini, Guido

AU - Lucesole, Moira

AU - Poloni, Antonella

AU - Offidani, Massimo

AU - Candela, Marco

AU - Centurioni, Riccardo

AU - Leoni, Pietro

PY - 2004/1

Y1 - 2004/1

N2 - Chemotherapy followed by autologous transplantation may be an efficient salvage treatment in malignant lymphomas. We investigated the feasibility, tolerability and efficacy of an outpatient schedule of dexamethasone, cytarabine and cisplatin (DHAP), followed by peripheral blood progenitor cell autografting as salvage treatment in patients with high grade (HG), low grade (LG) non-Hodgkin's lymphoma (NHL) and Hodgkin's Disease (HD). A total of 159 DHAP courses (median: 2, range: 1-5), was administered on outpatient basis to 79 patients (31 LG-NHL, 28 HG-NHL and 20 HD), with the intention to mobilize and to transplant. A successful collection was not achieved in 40% LG-NHL, 10% HD and 20% HG-NHL patients. The risk to fail the collection was significantly related to the number of previous chemotherapy courses (>6) (P = 0.005, RR = 1.4), to the pretransplant status (P = 0.04, RR = 13.5) and to the previous fludarabine administration (P = 0.01, RR = 20). High dose therapy (HDT) was feasible in 60 patients (76%). The overall treatment related mortality was 3.8%. The overall response rate (ORR) was 81% with a 57.6% overall survival (OS) at 62 months (95% CI: 45-69.3%) and a progression free survival (PFS) of 42% at 74 months (95% CI: 26.7-58%). The diagnosis of HG-NHL and the non-response to DHAP resulted to reduce respectively the OS (P = 0.007, RR = 2.8) and PFS probability (P = 0.01, RR = 4.1). In conclusion this outpatient schedule of DHAP is a well tolerated, efficient salvage and mobilizing regimen not only in HG-NHL, but also in LG-NHL and in HD. Randomized studies are needed to better define the role of DHAP in LG-NHL and HD patients.

AB - Chemotherapy followed by autologous transplantation may be an efficient salvage treatment in malignant lymphomas. We investigated the feasibility, tolerability and efficacy of an outpatient schedule of dexamethasone, cytarabine and cisplatin (DHAP), followed by peripheral blood progenitor cell autografting as salvage treatment in patients with high grade (HG), low grade (LG) non-Hodgkin's lymphoma (NHL) and Hodgkin's Disease (HD). A total of 159 DHAP courses (median: 2, range: 1-5), was administered on outpatient basis to 79 patients (31 LG-NHL, 28 HG-NHL and 20 HD), with the intention to mobilize and to transplant. A successful collection was not achieved in 40% LG-NHL, 10% HD and 20% HG-NHL patients. The risk to fail the collection was significantly related to the number of previous chemotherapy courses (>6) (P = 0.005, RR = 1.4), to the pretransplant status (P = 0.04, RR = 13.5) and to the previous fludarabine administration (P = 0.01, RR = 20). High dose therapy (HDT) was feasible in 60 patients (76%). The overall treatment related mortality was 3.8%. The overall response rate (ORR) was 81% with a 57.6% overall survival (OS) at 62 months (95% CI: 45-69.3%) and a progression free survival (PFS) of 42% at 74 months (95% CI: 26.7-58%). The diagnosis of HG-NHL and the non-response to DHAP resulted to reduce respectively the OS (P = 0.007, RR = 2.8) and PFS probability (P = 0.01, RR = 4.1). In conclusion this outpatient schedule of DHAP is a well tolerated, efficient salvage and mobilizing regimen not only in HG-NHL, but also in LG-NHL and in HD. Randomized studies are needed to better define the role of DHAP in LG-NHL and HD patients.

KW - Autologous transplant

KW - DHAP

KW - Mobilization

KW - Non-Hodgkin lymphoma

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=10744223888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223888&partnerID=8YFLogxK

U2 - 10.1046/j.0902-4441.2004.00171.x

DO - 10.1046/j.0902-4441.2004.00171.x

M3 - Article

C2 - 14962257

AN - SCOPUS:10744223888

VL - 72

SP - 10

EP - 17

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -